Global pharmaceutical manufacturer AstraZeneca has admitted that its Covid-19 vaccine, developed by researchers from the Oxford University, can cause a rare side effect of blood clotting and low platelet count after immunisation. In India, the same vaccine, called Covishield and manufactured by the Pune-based Serum Institute, has been administered through 175 crore doses. Understandably, this raises questions as to the safety of the jab all of us took.

The company made this admission of a side effect, Thrombosis with Thrombocytopenia Syndrome (TTS), in court as it faces a lawsuit alleging severe harm and deaths caused by the vaccine, according to The Daily Telegraph. While this may be the company’s first admission in court, TTS has been well-documented and accepted in scientific literature. The first cases came to light within months of the vaccination drives beginning in Europe, with some countries halting the use of the AstraZeneca vaccine for a while.